GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » EPS (Diluted)

Lifecore Biomedical (Lifecore Biomedical) EPS (Diluted) : $-3.32 (TTM As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical EPS (Diluted)?

Lifecore Biomedical's Earnings per Share (Diluted) for the three months ended in May. 2023 was $-1.19. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2023 was $-3.32.

Lifecore Biomedical's EPS (Basic) for the three months ended in May. 2023 was $-1.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in May. 2023 was $-3.32.

Lifecore Biomedical's EPS without NRI for the three months ended in May. 2023 was $-0.51. Its EPS without NRI for the trailing twelve months (TTM) ended in May. 2023 was $-1.66.

During the past 3 years, the average EPS without NRIGrowth Rate was -56.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Lifecore Biomedical's highest 3-Year average EPS without NRI Growth Rate was 76.20% per year. The lowest was -56.60% per year. And the median was 12.45% per year.


Lifecore Biomedical EPS (Diluted) Historical Data

The historical data trend for Lifecore Biomedical's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical EPS (Diluted) Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -1.31 -1.10 -3.97 -3.32

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.24 -0.38 -0.42 -1.33 -1.19

Competitive Comparison of Lifecore Biomedical's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's PE Ratio falls into.



Lifecore Biomedical EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Lifecore Biomedical's Diluted EPS for the fiscal year that ended in May. 2023 is calculated as

Diluted EPS (A: May. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-99.563-0)/29.958
=-3.32

Lifecore Biomedical's Diluted EPS for the quarter that ended in May. 2023 is calculated as

Diluted EPS (Q: May. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-35.571-0)/30.318
=-1.17

EPS (Diluted) for the trailing twelve months (TTM) ended in May. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical  (NAS:LFCR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lifecore Biomedical EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318